Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival.
Oct 2010 - :1432-0851 [PMID:20960187]
[Cornforth AN] [Fowler AW] [Carbonell DJ] [Dillman RO]

Increases in serum TARC/CCL17 levels are associated with progression-free survival in advanced melanoma patients in response to dendritic cell-based immunotherapy.
Aug 2009 - J. Clin. Immunol.; 29(5):1573-2592 [PMID:19421847]
[Cornforth AN] [Lee GJ] [Fowler AW] [Carbonell DJ] [Dillman RO]

Lack of elevation of serum S100B in patients with metastatic melanoma as a predictor of outcome after induction with an autologous vaccine of proliferating tumor cells and dendritic cells.
May 2008 - Cancer Biother. Radiopharm.; 23(2):1557-8852 [PMID:18454690]
[Schiltz PM] [Dillman RO] [Korse CM] [Cubellis JM] [Lee GJ] [De Gast GC]

Patient-specific dendritic-cell vaccines for metastatic melanoma.
Sep 2006 - N. Engl. J. Med.; 355(11):1533-4406 [PMID:16971731]
[Dillman RO] [Selvan SR] [Schiltz PM]